About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Alzheimer's Disease Clinical Trials in Phoenix | 240 Studies

Clinical Trials Alzheimer's DiseasePhoenix

Alzheimer's Disease Clinical Trials in Phoenix

Find 240 clinical trials for alzheimer's disease near Phoenix, Arizona. Connect with research centers in your area.

All Alzheimer's Disease trials nationwide All trials in Phoenix

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 1-20 of 240 trials

CompletedA Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.NCT04777409·Phoenix, Arizona and 497 others

Alzheimer's Disease Trials in Other Cities

New York Los Angeles Chicago Houston Philadelphia San Antonio

Data from ClinicalTrials.govTerms

CompletedEPIC: An Intervention for Early-stage AD Dyads - Adapted for Virtual DeliveryEPIC II (Early-Stage Partners in Care) is a research project designed to assist people with early-stage memory loss and their care partners by providing early-stage related…NCT03144921·Phoenix, Arizona

CompletedELND005 Long-Term Follow-up Study in Subjects With Alzheimer's DiseaseThe purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail…NCT00934050·Phoenix, Arizona and 37 others

TerminatedOpen-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial of LMTM continued access to therapy and to evaluate the long-term…NCT02245568·Phoenix, Arizona and 134 others

CompletedEffect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on DonepezilPrimary Objective: \- To demonstrate the efficacy of at least one dose of SAR110894 (H3 receptor antagonist) in comparison to placebo on cognitive performance in patients with…NCT01266525·Gilbert, Arizona and 81 others

CompletedDHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's DiseaseThe purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate…NCT00440050·Birmingham, Alabama and 50 others

TerminatedProgress of Mild Alzheimer's Disease in Participants on Solanezumab Versus PlaceboTo test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.NCT01900665·Phoenix, Arizona and 197 others

CompletedSafety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's DiseaseThe purpose of this study is to investigate efficacy and safety of different doses of AC-3933 in patients with mild to moderate Alzheimer's Disease.NCT00359944·LIttle Rock, Alaska and 33 others

CompletedA Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On MemantineThis is a randomized double-blind Placebo-controlled, Phase 2 study comparing bryostatin to placebo for the treatment of moderately severe to severe Alzheimer's disease in…NCT03560245·Fresno, California and 27 others

Active not recruitingA Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.NCT04437511·Gilbert, Arizona and 273 others

RecruitingA Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90…NCT06887192·Phoenix, Arizona and 54 others

TerminatedStudy of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's DiseaseThe purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's…NCT01969123·Phoenix, Arizona and 81 others

Enrolling by invitationGeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) GenotypeThe purpose of the Alzheimer's Prevention Registry GeneMatch program is to identify a large group of people interested in participating in research studies or clinical trials…NCT02564692·Phoenix, Arizona

CompletedAnti-viral Therapy in Alzheimer's DiseaseAnti-viral therapy in Alzheimer's disease will investigate the efficacy of treating patients with mild Alzheimer's disease with the U.S.A marketed generic anti-viral drug Valtrex…NCT03282916·Phoenix, Arizona and 2 others

TerminatedA 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's DiseaseTo evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.NCT01766336·Birmingham, Alabama and 45 others

TerminatedA Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early ADThis is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B.NCT03919162·Phoenix, Arizona and 21 others

TerminatedA Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's DiseaseThe purpose of this study is to evaluate the safety and efficacy of five fixed dosage levels of FK962 or placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease.NCT00087724·Phoenix, Arizona and 83 others

Terminated221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's DiseaseThe primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical…NCT02484547·Birmingham, Alabama and 179 others

CompletedTo Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid BurdenThe purpose of this study is to compare PET measurements of fibrillar amyloid burden using \[18F\]AZD4694.NCT00991419·Phoenix, Arizona

CompletedAmyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's DiseaseThis study in individuals with early Alzheimer's disease is designed to assess:(1) safety and tolerability (2) the capacity of ACC-001 and QS-21 adjuvant to reduce brain amyloid…NCT01227564·Phoenix, Arizona and 39 others

Page 1 of 12Next

Other Conditions in Phoenix

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia